Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
24.95(c) 24.7(c) 24.4(c) 24.4(c) 23.75(c) Last
304 526 218 665 246 521 201 111 360 859 Volume
-0.20% -1.00% -1.21% 0.00% -2.66% Change
More quotes
Financials ($)
Sales 2017 12,1 M
EBIT 2017 -90,8 M
Net income 2017 -93,9 M
Finance 2017 88,1 M
Yield 2017 -
Sales 2018 17,1 M
EBIT 2018 -93,2 M
Net income 2018 -96,6 M
Finance 2018 99,7 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 48,7x
EV / Sales2018 33,9x
Capitalization 677 M
More Financials
Company
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.Its products include Omadacycline and Sarecycline.The company was founded in February 2001 and is... 
Sector
Biotechnology & Medical Research
Calendar
10/17 | 06:00pmInvestor Day
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
10/09 PARATEK PHARMACEUTICALS INC : Today's Research Reports on Stocks to Watch: Parat..
10/06 Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In ..
10/06 Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Ph..
10/05 REPORTS FROM PARATEK PHARMACEUTICALS : development of a novel aminomethylcycline..
10/04 PARATEK PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
10/02 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
09/27 PARATEK PHARMACEUTICALS : to Present New Omadacycline Data at IDWeek 2017
09/25 Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017
09/25 PARATEK PHARMACEUTICALS : Omadacycline Receives Qualified Infectious Disease Pro..
09/21 PARATEK PHARMACEUTICALS INC. : to Host Investor Day on October 17, 2017
More news
Sector news : Bio Therapeutic Drugs
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/16$PRTK D1 Investor mtg tomorrow - maybe algos give a BTD opp  
10/14Paratek Pharmaceuticals, Inc. $PRTK Downgraded by Zacks Investment Research  
10/12Paratek Pharmaceuticals $PRTK Earns Daily Coverage Optimism Rating of 0.17  
10/12Get the latest news and updates for $VREX $UTMD $OPGN $NBEV $PRTK automatical.. 
10/11Paratek Pharmaceuticals downgraded by Zacks Investment Research to sell.  
More tweets
Qtime:33
News from SeekingAlpha
09/27 Paratek Pharmaceuticals (PRTK) Presents At Ladenburg Thalmann 2017 Healthcare..
09/21 Nabriva Looks To Another Phase 3 To Seal The Deal
09/21 Paratek's omadacycline granted additional QIDP status in U.S.
09/12 Paratek Pharmaceuticals (PRTK) Presents At Rodman & Renshaw 19th Annual Globa..
09/11 NABRIVA THERAPEUTICS : One Of The Biggest Binary Events Of September
Chart PARATEK PHARMACEUTICALS IN
Duration : Period :
Paratek Pharmaceuticals In Technical Analysis Chart | PRTK | US6993743029 | 4-Traders
Technical analysis trends PARATEK PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 43,4 $
Spread / Average Target 78%
EPS Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & CMO
Douglas W. Pagán Chief Financial & Accounting Officer
Paul McGovern Vice President-Clinical & Medical Affairs
Thomas John Dietz Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICALS INC58.44%677
GILEAD SCIENCES13.35%106 002
REGENERON PHARMACEUTICALS20.67%47 464
VERTEX PHARMACEUTICALS107.56%38 551
ACTELION23.24%29 919
GENMAB22.08%13 910